Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of ZYTIGA is substantial.
Clinical Added Value
moderate
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy.
Listen
